Spin off from CNRS and AMU, Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous and secreted protein modulating the pain signal. Our ambition : become the reference player in the field of pain by designing and proposing new active pharmaceutical ingredients for non-opioid analgesics, in a context marked by the opioid crisis, through the development of a first in class polypeptides derived from TAFA4 and its peptide derivatives. We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain - mild, moderate and severe -, as well as for the prevention of chronic pain. Our medium-term strategic objective is to enter into partnership agreements with major pharmaceutical companies or specialized international distributors who will be able to bring the products resulting from the TAFA4 technology to the market.